Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) and Protara Therapeutics (NASDAQ:TARA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.
Institutional & Insider Ownership
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Quoin Pharmaceuticals and Protara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quoin Pharmaceuticals | N/A | -334.41% | -125.15% |
| Protara Therapeutics | N/A | -36.38% | -33.81% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quoin Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Protara Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Protara Therapeutics has a consensus price target of $21.40, indicating a potential upside of 306.84%. Given Protara Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Quoin Pharmaceuticals.
Volatility & Risk
Quoin Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Earnings & Valuation
This table compares Quoin Pharmaceuticals and Protara Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quoin Pharmaceuticals | N/A | N/A | -$8.96 million | ($31.73) | -0.25 |
| Protara Therapeutics | N/A | N/A | -$44.60 million | ($1.32) | -3.98 |
Protara Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Protara Therapeutics beats Quoin Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
About Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
